IPSC Company Profile and Key Details

Q: Who are the executives of IPSC?

Dr. Luis BorgesChief Scientific OfficerDr. Osvaldo Flores Ph.D.Pres, Chief Executive Officer & DirectorDr. Michael C. DiemChief Bus. OfficerDr. Hyam I. Levitsky M.D.Pres of R&DMr. Kenneth J. Dow J.D.Senior Vice President of Gen. CounselMr. Douglas Carr C.P.A.Vice President of Fin. & Operations and Sec.Dr. Michael C. Diem M.D.Chief Financial OfficerMr. Douglas Carr CPASenior Vice President of Fin. & Operations and Sec.Dr. Shane Williams Ph.D.Chief People OfficerDr. Adrienne Farid Ph.D.Chief Operating Officer & Head of Early Devel.Dr. Gregory Russotti Ph.D.Interim Pres & Chief Executive OfficerMichael Naso Ph.D.Senior Vice President of Cell EngineeringMr. Mark WalletHead of Immunology & Vice President

NASDAQ : IPSC

Century Therapeutics

$2.17

-0.07500005-3.35%

Open: 1:25 PM

65.76

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Century Therapeutics, Inc. (IPSC) stock declined over -3.35%, trading at $2.17 on NASDAQ, down from the previous close of $2.24. The stock opened at $2.25, fluctuating between $2.15 and $2.26 in the recent session.

Stock Snapshot

2.24

Prev. Close

187.42M

Market Cap

2.145

Day Low

-2.04

P/E Ratio

-1.06

EPS (TTM)

-1.7

Cash Flow per Share

2.25

Open

86.57M

Number of Shares

2.26

Day High

52.33%

Free Float in %

3.09

Book Value

203.02K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 21, 2026	2.23	2.24	2.18	2.24	710.77K
Jul 20, 2026	2.27	2.30	2.14	2.19	861.44K
Jul 17, 2026	2.23	2.36	2.19	2.25	1.1M
Jul 16, 2026	2.18	2.27	2.12	2.26	1.07M
Jul 15, 2026	2.16	2.21	2.09	2.17	602.78K
Jul 14, 2026	2.21	2.25	2.10	2.13	1.65M
Jul 13, 2026	2.24	2.24	2.08	2.20	1.71M
Jul 10, 2026	2.31	2.31	2.19	2.25	1.2M
Jul 09, 2026	2.40	2.46	2.27	2.31	1.29M
Jul 08, 2026	2.40	2.44	2.28	2.43	1.27M
Jul 07, 2026	2.40	2.42	2.28	2.31	1.51M
Jul 06, 2026	2.42	2.47	2.31	2.40	1.03M
Jul 02, 2026	2.38	2.49	2.36	2.43	839.79K
Jul 01, 2026	2.42	2.50	2.29	2.39	2.02M
Jun 30, 2026	2.38	2.55	2.34	2.45	4.68M
Jun 29, 2026	2.35	2.50	2.17	2.41	1.87M
Jun 26, 2026	2.28	2.50	2.27	2.32	16.99M
Jun 25, 2026	2.29	2.50	2.28	2.30	1.01M
Jun 24, 2026	2.45	2.49	2.28	2.29	1.1M
Jun 23, 2026	2.24	2.41	2.22	2.41	1.26M

Contact Details

Philadelphia, PA 19104

United States

https://www.centurytx.com 267 817 5790

About Company

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.

Stock Peers

ARGX

28.55+3.37%

argenx SE$874.74 REGN

3.04+0.45%

Regeneron Pharmaceuticals, Inc.$675.19 MDGL

11.1+2.07%

Madrigal Pharmaceuticals, Inc.$546.79 UTHR

6.49+1.23%

United Therapeutics Corporation$535.83 VRTX

1.5+0.31%

Vertex Pharmaceuticals Incorporated$482.00 KRYS

-0.16-0.05%

Krystal Biotech, Inc.$339.06 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

8.11+2.61%

BeOne Medicines AG$318.69 PRAX

13.44+4.41%

Praxis Precision Medicines, Inc.$317.87 LGND

11.48+3.90%

Ligand Pharmaceuticals Incorporated$305.47

Frequently Asked Questions

What is the current Century Therapeutics, Inc. (IPSC) stock price?

Century Therapeutics, Inc. (NASDAQ: IPSC) stock price is $2.17 in the last trading session. During the trading session, IPSC stock reached the peak price of $2.26 while $2.15 was the lowest point it dropped to. The percentage change in IPSC stock occurred in the recent session was -3.35% while the dollar amount for the price change in IPSC stock was - $0.08.

IPSC's industry and sector of operation?

The NASDAQ listed IPSC is part of Biotechnology industry that operates in the broader Healthcare sector. Century Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IPSC?

Dr. Luis Borges
Chief Scientific Officer
Dr. Osvaldo Flores Ph.D.
Pres, Chief Executive Officer & Director
Dr. Michael C. Diem
Chief Bus. Officer
Dr. Hyam I. Levitsky M.D.
Pres of R&D
Mr. Kenneth J. Dow J.D.
Senior Vice President of Gen. Counsel
Mr. Douglas Carr C.P.A.
Vice President of Fin. & Operations and Sec.
Dr. Michael C. Diem M.D.
Chief Financial Officer
Mr. Douglas Carr CPA
Senior Vice President of Fin. & Operations and Sec.
Dr. Shane Williams Ph.D.
Chief People Officer
Dr. Adrienne Farid Ph.D.
Chief Operating Officer & Head of Early Devel.
Dr. Gregory Russotti Ph.D.
Interim Pres & Chief Executive Officer
Michael Naso Ph.D.
Senior Vice President of Cell Engineering
Mr. Mark Wallet
Head of Immunology & Vice President

How IPSC did perform over past 52-week?

IPSC's closing price is 414.94% higher than its 52-week low of $0.44 where as its distance from 52-week high of $3.04 is -26.32%.

How many employees does IPSC have?

Number of IPSC employees currently stands at 78.

Link for IPSC official website?

Official Website of IPSC is: https://www.centurytx.com

How do I contact IPSC?

IPSC could be contacted at phone 267 817 5790 and can also be accessed through its website. IPSC operates from 3675 Market Street, Philadelphia, PA 19104, United States.

How many shares of IPSC are traded daily?

IPSC stock volume for the day was 203.02K shares. The average number of IPSC shares traded daily for last 3 months was 1.27M.

What is the market cap of IPSC currently?

The market value of IPSC currently stands at $187.42M with its latest stock price at $2.17 and 86.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	78
Beta	1.56
Sales or Revenue	$2.24M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	78
Beta	1.56
Sales or Revenue	$2.24M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

IPSC Company Profile and Key Details

Century Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Valuation Metrics